ECM
TXMD icon

ETrade Capital Management’s TherapeuticsMD TXMD Stock Holding History

ETrade Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-500
Closed -$27K – 909
2020
Q1 		$27K Buy
+500
New +$49.6K ﹤0.01% 742

Other funds holding TXMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ETrade Capital Management's TXMD Position: Q2 2020 in Review

ETrade Capital Management sold out of TherapeuticsMD (TXMD) in Q2 2020, closing a stake of 500 shares — an estimated $27K sold.

ETrade Capital Management first reported a position in TXMD in Q1 2020 and held it in 1 quarter. The position peaked at $27K in Q1 2020. 149 funds tracked by Wall St. Rank hold TXMD as of Q2 2020.

  • ETrade Capital Management reported no remaining TherapeuticsMD position as of Q2 2020 after selling out during the quarter.
  • ETrade Capital Management sold 500 TherapeuticsMD shares in Q2 2020, an estimated $27K.
  • ETrade Capital Management first reported a position in TherapeuticsMD in Q1 2020 and held it in 1 quarter.
  • ETrade Capital Management's TherapeuticsMD position peaked at $27K in Q1 2020.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2020.

Based on ETrade Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.